Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting

Novel TBL1 targeting strategy drives nuclear β-catenin degradation, inhibits oncogenic transcription, and demonstrates potent anti-tumor activity in complex solid tumors The company continues to build clinical momentum in hepatocellular carcinoma while expanding development into...